



## (51) International Patent Classification:

A61P 3/06 (2006.01) C07K 16/28 (2006.01)  
A61P 13/12 (2006.01) C07K 16/18 (2006.01)

## (21) International Application Number:

PCT/US2020/066377

## (22) International Filing Date:

21 December 2020 (21.12.2020)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/953,097 23 December 2019 (23.12.2019) US

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way,  
South San Francisco, California 94080 (US).

(72) Inventors: **SCALES, Suzanna Jane**; c/o Genentech, Inc.,  
1 DNA Way, South San Francisco, California 94080 (US).  
**GUPTA, Nidhi**; 421 Luff Lane, Redwood City, California  
94065 (US). **PETERSON, Andrew Scott**; 1177 De Haro  
Street, San Francisco, California 94107 (US).

(74) Agent: **DOHERTY, Elizabeth** et al.; 125 Cambridge Park  
Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: APOLIPOPROTEIN L1-SPECIFIC ANTIBODIES AND METHODS OF USE






Figure 1G



(57) Abstract: This disclosure provides anti-apolipoprotein L1 (APOL1) antibodies, including anti-APOL1 antibodies that distinguish the G0 and G1 forms from the G2 form of APOL1, distinguish APOL1 found on podocytes from that found on HDL particles in serum, and distinguish APOL1 from apolipoproteins L2, L3, L4 and L6 (APOL2, APOL3, APOL4 and APOL6), and methods of using the same.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

**(88) Date of publication of the international search report:**

05 August 2021 (05.08.2021)